Patents by Inventor Teru Okitsu

Teru Okitsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10047353
    Abstract: Recombinant collagenases with a stable specific activity and enzyme agents for cell and tissue dissociation such a recombinant are provided. The recombinant collagenase is derived from Grimontia hollisae-derived collagenase is characterized by having, from the N terminus to the C terminus, a collagenase catalytic domain, a linker region sequence, and a prepeptidase C terminal domain, which Grimontia hollisae-derived recombinant collagenase does not comprise at least the prepeptidase C terminal domain. The obtained recombinant collagenase has a high and stable specific activity.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: August 14, 2018
    Assignees: Nippi, Incorporated, The University of Tokyo
    Inventors: Naoko Teramura, Katsumasa Iijima, Osamu Hayashida, Keisuke Tanaka, Shunji Hattori, Teru Okitsu, Shoji Takeuchi
  • Publication number: 20170218352
    Abstract: Recombinant collagenases with a stable specific activity and enzyme agents for cell and tissue dissociation such a recombinant are provided. The recombinant collagenase is derived from Grimontia hollisae-derived collagenase is characterized by having, from the N terminus to the C terminus, a collagenase catalytic domain, a linker region sequence, and a prepeptidase C terminal domain, which Grimontia hollisae-derived recombinant collagenase does not comprise at least the prepeptidase C terminal domain. The obtained recombinant collagenase has a high and stable specific activity.
    Type: Application
    Filed: March 6, 2015
    Publication date: August 3, 2017
    Inventors: Naoko Teramura, Katsumasa Iijima, Osamu Hayashida, Keisuke Tanaka, Shunji Hattori, Teru Okitsu, Shoji Takeuchi
  • Publication number: 20140248698
    Abstract: The one aspect of the present invention aims to provide a novel cloning method for human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), which method is based on culture of dispersed single cells without addition of an apoptotic agent. More specifically, the one aspect of the present invention aims to provide a cloning method for hESCs and hiPSCs based on culture of dispersed single cells utilizing shear stress. The above problem is solved by providing a method for culturing dispersed single pluripotent cells, wherein the dispersed single cells are cultured under laminar flow conditions.
    Type: Application
    Filed: October 22, 2012
    Publication date: September 4, 2014
    Applicant: ARKRAY, INC.
    Inventors: Hidetoshi Kotera, Kazuya Tatsumi, Ryuji Yokokawa, Takashi Tada, Shogo Nagata, Teru Okitsu, Atsuhito Okonogi, Yuichiro Noda, Naoyuki Nakanishi, Taku Matsumura, Takashi Osumi
  • Patent number: 8822722
    Abstract: To provide a fluorescent hydrogel having superior detectability of saccharides such as glucose and minimal invasiveness, a method for producing the same, and a sensor for measuring saccharides using the same. A florescent hydrogel having a structure represented by the following chemical formula 1, a method for producing the same, and a sensor for measuring saccharides using the same.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: September 2, 2014
    Assignees: Terumo Kabushiki Kaisha, The University of Tokyo
    Inventors: Yun-Jung Heo, Hideaki Shibata, Tetsuro Kawanishi, Shoji Takeuchi, Yukiko Matsunaga, Teru Okitsu
  • Publication number: 20130267800
    Abstract: To provide a fluorescent hydrogel having superior detectability of saccharides such as glucose and minimal invasiveness, a method for producing the same, and a sensor for measuring saccharides using the same. A florescent hydrogel having a structure represented by the following chemical formula 1, a method for producing the same, and a sensor for measuring saccharides using the same.
    Type: Application
    Filed: September 7, 2011
    Publication date: October 10, 2013
    Applicants: THE UNIVERSITY OF TOKYO, TERUMO KABUSHIKI KAISHA
    Inventors: Yun-Jung Heo, Hideaki Shibata, Tetsuro Kawanishi, Shoji Takeuchi, Yukiko Matsunaga, Teru Okitsu
  • Patent number: 7919080
    Abstract: The present invention provides a cell line which can be substituted for ? cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: April 5, 2011
    Inventors: Naoya Kobayashi, Noriaki Tanaka, Teru Okitsu, Ji-Won Yoon, Hee-Sook Jun, Seungjin Shin
  • Publication number: 20090209033
    Abstract: The present invention provides a cell line which can be substituted for ? cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.
    Type: Application
    Filed: November 13, 2007
    Publication date: August 20, 2009
    Inventors: Naoya Kobayashi, Noriaki Tanaka, Teru Okitsu, Ji-Won Yoon, Hee-Sook Jun, Seungjin Shin
  • Patent number: 7312077
    Abstract: The present invention provides a cell line which can be substituted for ? cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: December 25, 2007
    Inventors: Naoya Kobayashi, Noriaki Tanaka, Teru Okitsu, Ji-Won Yoon, Hee-Sook Jun, Seungjin Shin
  • Publication number: 20040166098
    Abstract: The present invention provides a cell line which can be substituted for &bgr; cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.
    Type: Application
    Filed: June 2, 2003
    Publication date: August 26, 2004
    Inventors: Naoya Kobayashi, Noriaki Tanaka, Teru Okitsu, Ji-Won Yoon, Hee-Sook Jun, Seungjin Shin